ArticleFrontiers in oncology2025
The clinical significance of hyperthermic intraperitoneal chemotherapy combined with PD-1 inhibitor and systemic chemotherapy for advanced gastric cancer patients with peritoneal metastasis: a single-center retrospective study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tumor-associated macrophages in gastric cancer peritoneal metastasis: orchestrating immune evasion, niche remodeling, and therapeutic resistance.Frontiers in immunology · 2026Review
- Hyperthermia enhances the efficacy of PD-1 inhibitor plus chemotherapy in PD-L1 CPS-negative advanced gastric cancer.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Peritoneal metastasis (PM) in gastric cancer (GC) correlates with a poor prognosis. PD-1 inhibitor has significantly transformed the treatment landscape for GC, but data on the combination of HIPEC with PD-1 inhibitor and systemic chemotherapy are limited. This study evaluated the efficacy and safety of this triplet therapy as first-line treatment for GC with PM. Methods: This was a retrospective, single-center study that included 34 advanced GC patients with PM. All patients received HIPEC combined with PD-1 inhibitor and systemic chemotherapy as first-line treatment (Nov 2021-Jun 2024). Primary endpoints were progression-free survival (PFS) and the duration of ascites control. Secondary endpoints were overall survival (OS) and adverse events (AEs). Results: Median PFS was 7.8 months (range: 0.8-20.8), median OS was 14.3 months (range: 1.7-23.9). Patients diagnosed with moderate amount of ascites had significantly poorer PFS than with none or small amount of ascites (HR = 2.804, Conclusion: HIPEC combined with PD-1 inhibitor and systemic chemotherapy demonstrated encouraging survival and ascites control with an acceptable safety profile in GC patients with PM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.